Anti-CLDN18.2/CD3 Bispecific Formulation for pH and Thermal Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific antibody formulations lack stability and require complex formulation conditions due to varying antibody structures and CDR sequences, making it difficult to ensure safety and efficacy for human use.
Innovation Solution
A pharmaceutical formulation comprising an anti-Claudin18.2 and CD3 bispecific antibody with a buffer, stabilizer, surfactant, and optionally a chelating agent, which provides stability against temperature and pH variations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If complex formulation conditions are used to maintain antibody stability, then stability is improved, but formulation complexity increases
Solution Approach 1:
The patent optimizes specific formulation parameters including buffer pH (5.0-7.0), stabilizer concentration (10-50 mM), and surfactant concentration (0.01-0.1%) to achieve stable antibody formulations. By systematically adjusting these parameters, the patent finds optimal conditions that maintain antibody stability without requiring overly complex formulation systems.
2Stability of the object's composition
If formulation is optimized for each antibody, then stability is improved, but manufacturing time increases
Solution Approach 1:
The patent establishes a preliminary formulation framework with recommended buffer types, stabilizer classes, and surfactant options that can be quickly adapted to different antibodies. This pre-planned approach allows formulators to make rapid decisions based on antibody characteristics without conducting extensive de novo optimization for each antibody, thereby reducing development time while maintaining stability.
3Ease of manufacture
If simple formulation formula is used, then ease of manufacture is improved, but stability is worsened
Solution Approach 1:
The patent identifies formulation components with multiple functions: buffers that maintain pH and provide ionic strength, stabilizers that prevent aggregation and maintain solubility, and surfactants that reduce surface tension and prevent adsorption. By selecting components that perform multiple functions simultaneously, the patent achieves adequate stability with relatively simple formulation compositions.
Data Source
AI summary
The present invention relates to preparations containing anti-CLDN18.2/CD3 antibody, in particular to pharmaceutical preparations comprising an anti-CLDN18.2/CD3 antibody, a buffer, a stabilizer and a surfactant. In addition, the present invention also relates to the use of the preparations in disease treatment or prevention.